SAN FRANCISCO, CA–(Marketwired – May 12, 2016) – Biotech and medtech startups are not confined to the U.S. and Europe. Unmet medical needs exist all over the globe, and they create a powerful vacuum that sucks in bright minds and risk-taking capitalists. Australia is a good example: The regulatory environment supports first-in-human experimentation and entrepreneurship. Healthcare Analyst Dennis Hulme of Edison Investment Research is headquartered in Sydney, and in this interview with The Life Sciences Report, he cites a group of Australian medtech and biotech names that investors should look at very carefully.
Included in this interview is: Regeneus Ltd. (ASX: RGS).
TLSR: Excluding hematopoietic stem cell transplants, we are two decades into development of cell therapies. Why do you think cell therapy platforms have taken so long to get into pivotal stages?
DH: Part of it is the notion that these treatments are novel, and it follows that they are not particularly well understood. It’s taken time to get a good understanding of the mechanism of action, learning about the cellular secretions — for example, cytokines — that are responsible for the majority of the effects you see. It’s taken some time to identify the most appropriate indications.
Another thing is that the primary outcome measure, or endpoint, in most of these studies has been safety. Thus far, trials have been mostly exploratory for efficacy. A number of the diseases being addressed by proposed cell therapies are…
Continue reading this interview:
Advantage: Australia. Biotechs Surge Ahead in Regenerative Medicine and Immuno-Oncology
About Streetwise Reports —
The Life Sciences Report
Investors rely on The Life Sciences Report
to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.
DISCLOSURE:
Regeneus Ltd. is a sponsor of Streetwise Reports. Dr. Dennis Hulme is wholly responsible for the validity of the statements. Statement and opinions expressed are the opinions of Dr. Hulme and not of Streetwise Reports or its officers. This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.
Please see Streetwise Reports’ terms of use and full legal disclaimer.
Jim Patrick
Email contact